Enter inventor name

Benoit Pugin

USPTO Granted Patents = 20 (Patent Applications = 3)

CIPO Patents = 4

Average Co-Inventor Count = 2.1

ph-index = 8

Forward Citations = 151(Granted Patents)

Location History:

Muchenstein, CH (2000)
M{umlaut over (u)}nchenstein, CH (2001)
Muenchenstein, CH (2007 - 2011)
Munchenstein, CH (1991 - 2013)

Company Filing History:

9 out of 6,850

Ciba-geigy Corporation

Destiny Pharma Limited

Novartis Finance Corporation

patents

where one patent can have more than one assignee

Years Active: 1991-2013

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8598371 - Bidentate chiral ligands for use in catalytic asymmetric addition reactions (2013-12-03),

2. 8084602 - Porphyrin derivatives and their use in photodynamic therapy (2011-12-27),

3. 7816525 - Process for the preparation of optically pure tetrahydropterins and derivatives, and specifically of optically pure tetrahydrofolic acid and derivatives thereof, by stereospecific hydrogenation (2010-10-19),

4. 7244841 - Porphyrin derivatives and their use in photodynamic therapy (2007-07-17),

5. 6169192 - Functionalized ferrocenyldiphosphines, a process for their preparation and their use (2001-01-02),

6. 6133464 - Chiral ferrocenyls (2000-10-17),

7. 6015919 - Dihalogenated ferrocenes and processes for the preparation thereof (2000-01-18),

8. 5925778 - Dihalogenated ferrocenes and processes for the preparation thereof (1999-07-20),

9. 5883283 - Process for the preparation of substituted 3-aminobenzonitriles (1999-03-16),

10. 5783715 - Silylated ferrocenyldiphosphines, silylated ferrocenyldiphosphines bound (1998-07-21),

11. 5777062 - Diphosphines bonded to side chains of polymers, and metal complexes (1998-07-07),

12. 5627293 - Silylated ferrocenyldiphosphines, silylated ferrocenyldiphosphines bound (1997-05-06),

13. 5432289 - Diphosphines containing silane groups, immobilized diphosphines and the (1995-07-11),

14. 5382729 - Diphosphines containing silane groups, immobilized diphosphins and the (1995-01-17),

15. 5308819 - Diphosphines containing silane groups, immobilised diphosphines and the (1994-05-03),

Title: Benoit Pugin: Innovator in Catalysis and Photodynamic Therapy

Introduction

Benoit Pugin, hailing from Munchenstein, Switzerland, is a prominent innovator known for his significant contributions to the fields of catalysis and medical therapies. With an impressive portfolio of 20 patents, Pugin has made considerable advancements that highlight his expertise and dedication to scientific innovation.

Latest Patents

Among his notable patents, Pugin has developed bidentate chiral ligands useful in catalytic asymmetric addition reactions. The compounds, identified by the formula (I), are designed to predominantly favor one diastereomer or exist as pure diastereomers. Additionally, he has explored porphyrin derivatives which serve critical roles in photodynamic therapy. His inventions facilitate the treatment of medical conditions requiring photodynamic agents, including pharmaceutical formulations, sterilizing solutions, and methods of treatment involving these compounds.

Career Highlights

Throughout his career, Benoit Pugin has worked with renowned companies, including Ciba-Geigy Corporation and Novartis AG. His time at these organizations has played a crucial role in shaping his research and innovative output, allowing him to lead projects that bridge the gap between chemical science and practical medical applications.

Collaborations

Pugin has collaborated with notable colleagues such as Felix Spindler and Manfred Muller, contributing to a dynamic exchange of ideas and fostering innovative approaches within his field. These collaborations have enabled him to broaden his research capabilities and enhance the impact of his patents.

Conclusion

Benoit Pugin stands out as a leading inventor, pushing the boundaries of chemical applications in both catalysis and medicine. His 20 patents reflect his commitment to innovation and his ability to translate complex scientific concepts into practical solutions, ultimately benefiting various sectors of society.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com